Sunitinib-containing carborane pharmacophore with the ability to inhibit tyrosine kinases receptors FLT3, KIT and PDGFR-β, exhibits powerful in vivo anti-glioblastoma activity

Malignant gliomas are the most common malignant and aggressive primary brain tumors in adults, the prognosis being—especially for glioblastomas—extremely poor. There are no effective treatments yet. However, tyrosine kinase receptor (TKR) inhibitors and boron neutron capture therapy (BNCT), together...

Fuld beskrivelse

Bibliografiske detaljer

Hovedforfatter:	Alamón, Catalina (author)
Andre forfattere:	Dávila Saralegui, Belén (author), García Melián, María Fernanda (author), Sánchez, Carina (author), Kovacs, Mariángeles (author), Trias, Emiliano (author), Barbeito, Luis (author), Gabay, Martín (author), Zeineh, Nidal (author), Gavish, Moshe (author), Teixidor, Francesc (author), Viñas, Clara (author), Couto, Marcos (author), Cerecetto, Hugo (author)
Format:	article
Sprog:	engelsk
Udgivet:	2020
Fag:	Carborane FLT3 Sub-G1 arrest Anti-tumor activity
Online adgang:	https://hdl.handle.net/20.500.12008/31990
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!